Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
DASL-HiCaP is a randomised phase 3 study aiming to demonstrate that the addition of a new oral hormonal therapy, darolutamide, to the standard radiation therapy and testosterone suppression, improves the outcomes of men with localised high-risk prostate cancer.
Primary Sponsor
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
1100
Final Accrual
1100
Trial Chairperson
Prof Christopher Sweeney and Assoc/Prof Tamim Niazi
Trial Contact
dasl.study@sydney.edu.au
Clinical Trial Registration
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Related Post
Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers
SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr
TROG’s inaugural Km’s for Cancer Research brings community together to support our work
LATEST NEWS: 9 December 2025 As we wrap up